Drug search by name

Votrient and Liver dysfunction

Result of checking the interaction of drug Votrient and disease Liver dysfunction for safety when used together.

Check result:

Votrient <> Liver dysfunction

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Severe and fatal hepatotoxicity has been observed with the use of pazopanib. No dose adjustment is required in patients with mild hepatic impairment. Pazopanib dose should be reduced to 200 mg per day in patients with moderate hepatic impairment. Pazopanib is not recommended in patients with severe hepatic impairment. It is recommended to monitor serum liver tests before starting treatment with pazopanib and at weeks 3, 5, 7, and 9. Thereafter, monitor at month 3 and at month 4, and as clinically indicated; periodic monitoring should then continue monthly. The use of this agent should be interrupted in patients presenting significant hepatic dysfunction and restart therapy only if clinically necessary and according to clinical recommendations.

Votrient

Generic Name: pazopanib

Brand Name: Votrient

Synonyms: n.a.

What is Votrient?